FY2025 EPS Estimates for EYPT Cut by Cantor Fitzgerald

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) – Investment analysts at Cantor Fitzgerald cut their FY2025 earnings estimates for shares of EyePoint Pharmaceuticals in a report issued on Thursday, May 8th. Cantor Fitzgerald analyst J. Kim now expects that the company will post earnings per share of ($3.15) for the year, down from their prior forecast of ($2.96). The consensus estimate for EyePoint Pharmaceuticals’ current full-year earnings is ($2.13) per share.

A number of other equities research analysts have also issued reports on EYPT. StockNews.com raised shares of EyePoint Pharmaceuticals to a “sell” rating in a report on Friday, March 14th. HC Wainwright reiterated a “buy” rating and issued a $22.00 target price on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. Finally, Chardan Capital cut their price target on shares of EyePoint Pharmaceuticals from $33.00 to $27.00 and set a “buy” rating for the company in a report on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating and eight have given a buy rating to the company. According to data from MarketBeat.com, EyePoint Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $25.29.

EyePoint Pharmaceuticals Stock Up 1.0%

Shares of NASDAQ:EYPT opened at $5.91 on Monday. EyePoint Pharmaceuticals has a 52-week low of $3.91 and a 52-week high of $13.99. The stock has a market cap of $406.67 million, a P/E ratio of -2.96 and a beta of 1.58. The business has a fifty day moving average of $5.99 and a two-hundred day moving average of $7.45.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.65) EPS for the quarter, meeting the consensus estimate of ($0.65). EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. The firm had revenue of $24.50 million during the quarter, compared to analysts’ expectations of $8.84 million.

Hedge Funds Weigh In On EyePoint Pharmaceuticals

A number of hedge funds have recently made changes to their positions in EYPT. Summit Investment Advisors Inc. grew its stake in shares of EyePoint Pharmaceuticals by 39.6% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,838 shares of the company’s stock valued at $51,000 after buying an additional 1,940 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of EyePoint Pharmaceuticals by 3,174.4% in the first quarter. GAMMA Investing LLC now owns 10,249 shares of the company’s stock valued at $56,000 after purchasing an additional 9,936 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in EyePoint Pharmaceuticals during the 4th quarter worth approximately $59,000. Virtus ETF Advisers LLC acquired a new stake in EyePoint Pharmaceuticals during the 4th quarter worth approximately $67,000. Finally, AlphaQuest LLC boosted its position in EyePoint Pharmaceuticals by 13,246.6% in the 4th quarter. AlphaQuest LLC now owns 9,743 shares of the company’s stock valued at $73,000 after buying an additional 9,670 shares during the period. Hedge funds and other institutional investors own 99.41% of the company’s stock.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.